ProQR Therapeutics NV (NASDAQ:PRQR) has earned a consensus rating of “Buy” from the six brokerages that are currently covering the company. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $17.17.

PRQR has been the subject of several research analyst reports. Leerink Swann restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Thursday, August 18th. JMP Securities restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Zacks Investment Research upgraded shares of ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research note on Wednesday, August 31st. Janney Montgomery Scott began coverage on shares of ProQR Therapeutics NV in a research note on Wednesday. They issued a “neutral” rating and a $7.00 price objective for the company. Finally, Chardan Capital began coverage on shares of ProQR Therapeutics NV in a research note on Monday, June 20th. They set a “neutral” rating and a $4.50 target price for the company.

An institutional investor recently raised its position in ProQR Therapeutics NV stock. Sabby Management LLC raised its stake in ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned approximately 0.64% of ProQR Therapeutics NV worth $732,000 at the end of the most recent reporting period. Institutional investors own 39.21% of the company’s stock.

Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.67 on Thursday. The firm’s market capitalization is $155.72 million. ProQR Therapeutics NV has a 12-month low of $3.48 and a 12-month high of $16.23. The company has a 50-day moving average price of $6.01 and a 200 day moving average price of $5.23.

ProQR Therapeutics NV (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.00. On average, equities analysts expect that ProQR Therapeutics NV will post ($2.09) earnings per share for the current year.

ProQR Therapeutics NV Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

5 Day Chart for NASDAQ:PRQR

Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with's FREE daily email newsletter.